Literature DB >> 9568682

Basal hepatic glucose production is regulated by the portal vein insulin concentration.

D K Sindelar1, C A Chu, P Venson, E P Donahue, D W Neal, A D Cherrington.   

Abstract

The ability of portal vein insulin to control hepatic glucose production (HGP) is debated. The aim of the present study was to determine, therefore, if the liver can respond to a selective decrease in portal vein insulin. Isotopic ([3H]glucose) and arteriovenous difference methods were used to measure HGP in conscious overnight fasted dogs. A pancreatic clamp (somatostatin plus basal portal insulin and glucagon) was used to control the endocrine pancreas. A 40-min control period was followed by a 180-min test period. During the latter, the portal vein insulin level was selectively decreased while the arterial insulin level was not changed. This was accomplished by stopping the portal insulin infusion and giving insulin peripherally at half the basal portal rate (PID, n=5). In a control group (n=5), the portal insulin infusion was not changed and glucose was infused to match the hyperglycemia that occurred in the PID group. A selective decrease of 120 pmol/l in portal vein insulin was achieved (basal, 150+/-36 to last 30 min, 30+/-12 pmol/l) in the absence of a change in the arterial insulin level (basal, 30+/-3 to last 30 min, 36+/-4 pmol/l). Neither arterial nor portal insulin levels changed in the control group (30+/-6 and 126+/-30 pmol/l, respectively). In response to the selective decrease in portal vein insulin, net hepatic glucose output (NHGO) increased significantly, from 8+/-1 (basal) to 30+/-6 and 14+/-2 micromol x kg(-1) x min(-1) by 15 min and the last 30 min (P < 0.05) of the experimental period, respectively. Arterial plasma glucose increased from 5.9+/-0.2 (basal) to 10.5+/-0.4 micromol/l (last 30 min). Three-carbon gluconeogenic precursor uptake fell from 11.2+/-2.9 (basal) to 5.9+/-0.7 micromol x kg(-1) x min(-1) (last 30 min), and thus a change in gluconeogenesis could not account for any of the increase in NHGO. With matched hyperglycemia (basal, 5.5+/-0.3 to last 30 min, 10.5+/-0.8 micromol/l) but no change in insulin, NHGO decreased from 12+/-1 (basal) to 0 (-1+/-6 micromol x kg(-1) x min(-1), last 30 min, P < 0.05) and hepatic gluconeogenic precursor uptake did not change (basal, 8.0+/-1.7 to last 30 min, 8.9+/-2.2 micromol x kg[-1] x min[-1]). Thus, the liver responds rapidly to a selective decrease in portal vein insulin by markedly increasing HGP as a result of increased glycogenolysis. These studies indicate that after an overnight fast, basal HGP (glycogenolysis) is highly sensitive to the hepatic sinusoidal insulin level.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568682     DOI: 10.2337/diabetes.47.4.523

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  34 in total

Review 1.  The role of the liver in type 2 diabetes.

Authors:  Peter Staehr; Ole Hother-Nielsen; Henning Beck-Nielsen
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

2.  Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action.

Authors:  Haruka Okamoto; Silvana Obici; Domenico Accili; Luciano Rossetti
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

3.  Central control of glucose homeostasis.

Authors:  Antonella Puglianiello; Stefano Cianfarani
Journal:  Rev Diabet Stud       Date:  2006-08-10

4.  Glucose autoregulation is the dominant component of the hormone-independent counterregulatory response to hypoglycemia in the conscious dog.

Authors:  Justin M Gregory; Noelia Rivera; Guillaume Kraft; Jason J Winnick; Ben Farmer; Eric J Allen; E Patrick Donahue; Marta S Smith; Dale S Edgerton; Phillip E Williams; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-16       Impact factor: 4.310

5.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Authors:  E Bugianesi; A Gastaldelli; E Vanni; R Gambino; M Cassader; S Baldi; V Ponti; G Pagano; E Ferrannini; M Rizzetto
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

6.  Elevated NEFA levels impair glucose effectiveness by increasing net hepatic glycogenolysis.

Authors:  S Kehlenbrink; S Koppaka; M Martin; R Relwani; M-H Cui; J-H Hwang; Y Li; R Basu; M Hawkins; P Kishore
Journal:  Diabetologia       Date:  2012-07-31       Impact factor: 10.122

7.  Elevated concentrations of liver enzymes and ferritin identify a new phenotype of insulin resistance: effect of weight loss after gastric banding.

Authors:  Amalia Gastaldelli; Lucia Perego; Michele Paganelli; Giorgio Sesti; Marta Hribal; Alberto O Chavez; Ralph A Defronzo; Antonio Pontiroli; Franco Folli
Journal:  Obes Surg       Date:  2008-09-24       Impact factor: 4.129

8.  Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target?

Authors:  David A D'Alessio
Journal:  Diabetes       Date:  2010-07       Impact factor: 9.461

9.  Portal glucose infusion-glucose clamp measures hepatic influence on postprandial systemic glucose appearance as well as whole body glucose disposal.

Authors:  Dan Zheng; Viorica Ionut; Vahe Mooradian; Darko Stefanovski; Richard N Bergman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-24       Impact factor: 4.310

10.  Chronic peripheral hyperinsulinemia in type 1 diabetic patients after successful combined pancreas-kidney transplantation does not affect ectopic lipid accumulation in skeletal muscle and liver.

Authors:  Marietta Stadler; Christian Anderwald; Giovanni Pacini; Stefan Zbýn; Miriam Promintzer-Schifferl; Martina Mandl; Martin Bischof; Stephan Gruber; Peter Nowotny; Anton Luger; Rudolf Prager; Michael Krebs
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.